Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients [8]

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 2, 2001, Pages 325-327

  Byl, Baudouin ^a   Baran, Daniel ^a   Jacobs, Frédérique ^a   Herschuelz, André ^a   Thys, Jean Pierre ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; GLUCOSE;

ADULT; AGED; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SPUTUM LEVEL; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; MALE; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEPHALOSPORINS; CHILD; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; SPUTUM;

EID: 0034884491     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children
2. Pharmacokinetics of amikacin in cystic fibrosis: A study of bronchial diffusion
3. Kinetic parameters of amikacin in cystic fibrosis children
4. Penetration of ceftazidime into bronchial secretions in critically ill patients
5. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment